126 related articles for article (PubMed ID: 37844869)
1. Pathologic Processing of Lung Cancer Resection Specimens After Neoadjuvant Therapy.
Weissferdt A; Leung CH; Lin H; Sepesi B; William WN; Swisher SG; Cascone T; Lee JJ; Pataer A
Mod Pathol; 2024 Jan; 37(1):100353. PubMed ID: 37844869
[TBL] [Abstract][Full Text] [Related]
2. Major pathologic response assessment and clinical significance of metastatic lymph nodes after neoadjuvant therapy for non-small cell lung cancer.
Liu X; Sun W; Wu J; Feng Y; Mao L; Chen M; Yang X; Wang H; Chi K; Yang Y; Lin D
Mod Pathol; 2021 Nov; 34(11):1990-1998. PubMed ID: 34253867
[TBL] [Abstract][Full Text] [Related]
3. Pathologic features of response to neoadjuvant anti-PD-1 in resected non-small-cell lung carcinoma: a proposal for quantitative immune-related pathologic response criteria (irPRC).
Cottrell TR; Thompson ED; Forde PM; Stein JE; Duffield AS; Anagnostou V; Rekhtman N; Anders RA; Cuda JD; Illei PB; Gabrielson E; Askin FB; Niknafs N; Smith KN; Velez MJ; Sauter JL; Isbell JM; Jones DR; Battafarano RJ; Yang SC; Danilova L; Wolchok JD; Topalian SL; Velculescu VE; Pardoll DM; Brahmer JR; Hellmann MD; Chaft JE; Cimino-Mathews A; Taube JM
Ann Oncol; 2018 Aug; 29(8):1853-1860. PubMed ID: 29982279
[TBL] [Abstract][Full Text] [Related]
4. Pathologic Response Evaluation in Neoadjuvant-Treated Lung Cancer.
Dacic S
Surg Pathol Clin; 2024 Jun; 17(2):287-293. PubMed ID: 38692811
[TBL] [Abstract][Full Text] [Related]
5. Association between pathologic response and survival after neoadjuvant therapy in lung cancer.
Deutsch JS; Cimino-Mathews A; Thompson E; Provencio M; Forde PM; Spicer J; Girard N; Wang D; Anders RA; Gabrielson E; Illei P; Jedrych J; Danilova L; Sunshine J; Kerr KM; Tran M; Bushong J; Cai J; Devas V; Neely J; Balli D; Cottrell TR; Baras AS; Taube JM
Nat Med; 2024 Jan; 30(1):218-228. PubMed ID: 37903504
[TBL] [Abstract][Full Text] [Related]
6. Immune-related histologic phenotype in pretreatment tumour biopsy predicts the efficacy of neoadjuvant anti-PD-1 treatment in squamous lung cancer.
Yuan P; Guo C; Li L; Ling Y; Guo L; Ying J
BMC Med; 2022 Oct; 20(1):403. PubMed ID: 36280845
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of Pathologic Response in Lymph Nodes of Patients With Lung Cancer Receiving Neoadjuvant Chemotherapy.
Pataer A; Weissferdt A; Vaporciyan AA; Correa AM; Sepesi B; Wistuba II; Heymach JV; Cascone T; Swisher SG
J Thorac Oncol; 2021 Aug; 16(8):1289-1297. PubMed ID: 33857666
[TBL] [Abstract][Full Text] [Related]
8. "Major pathologic response" in lymph nodes: a modified nodal classification for non-small cell lung cancer patients treated with neoadjuvant immunochemotherapy.
Deng H; Xiong S; Zhong R; Zheng Y; Liang H; Cheng B; Li J; Li F; Chen Z; Wang H; He J; Liang W
Exp Hematol Oncol; 2023 Apr; 12(1):40. PubMed ID: 37072866
[TBL] [Abstract][Full Text] [Related]
9. Different pathologic responses to neoadjuvant anti-PD-1 in primary squamous lung cancer and regional lymph nodes.
Ling Y; Li N; Li L; Guo C; Wei J; Yuan P; Tan F; Tao X; Wang S; Wang Z; Wu N; Wang J; Ying J; Gao S; He J
NPJ Precis Oncol; 2020 Dec; 4(1):32. PubMed ID: 33299121
[TBL] [Abstract][Full Text] [Related]
10. International Association for the Study of Lung Cancer Study of Reproducibility in Assessment of Pathologic Response in Resected Lung Cancers After Neoadjuvant Therapy.
Dacic S; Travis W; Redman M; Saqi A; Cooper WA; Borczuk A; Chung JH; Glass C; Lopez JM; Roden AC; Sholl L; Weissferdt A; Posadas J; Walker A; Zhu H; Wijeratne MT; Connolly C; Wynes M; Bota-Rabassedas N; Sanchez-Espiridion B; Lee JJ; Berezowska S; Chou TY; Kerr K; Nicholson A; Poleri C; Schalper KA; Tsao MS; Carbone DP; Ready N; Cascone T; Heymach J; Sepesi B; Shu C; Rizvi N; Sonett J; Altorki N; Provencio M; Bunn PA; Kris MG; Belani CP; Kelly K; Wistuba I;
J Thorac Oncol; 2023 Oct; 18(10):1290-1302. PubMed ID: 37702631
[TBL] [Abstract][Full Text] [Related]
11. Agreement on Major Pathological Response in NSCLC Patients Receiving Neoadjuvant Chemotherapy.
Weissferdt A; Pataer A; Vaporciyan AA; Correa AM; Sepesi B; Moran CA; Wistuba II; Roth JA; Shewale JB; Heymach JV; Kalhor N; Cascone T; Hofstetter WL; Lee JJ; Swisher SG
Clin Lung Cancer; 2020 Jul; 21(4):341-348. PubMed ID: 32279936
[TBL] [Abstract][Full Text] [Related]
12. [Histopathological features of squamous cell carcinoma of lung neoadjuvant immunotherapy focusing on responses].
Wei JC; Yuan P; Ling Y; Li L; Guo CY; Guo L; Xue LY; Ying JM
Zhonghua Bing Li Xue Za Zhi; 2021 May; 50(5):453-457. PubMed ID: 33915650
[No Abstract] [Full Text] [Related]
13. Major pathological response exhibited distinct prognostic significance for lung adenocarcinoma post different modalities of neoadjuvant therapy.
Xia L; Guo J; E H; Zhang W; Huang Y; Zhang L; Zhao D; Xie D; Wu C; Hou L
Histopathology; 2023 Apr; 82(5):691-703. PubMed ID: 36579364
[TBL] [Abstract][Full Text] [Related]
14. Controversies and challenges in the pathologic examination of lung resection specimens after neoadjuvant treatment.
Weissferdt A; Pataer A; Swisher SG; Heymach JV; Gibbons DL; Cascone T; Sepesi B
Lung Cancer; 2021 Apr; 154():76-83. PubMed ID: 33631448
[TBL] [Abstract][Full Text] [Related]
15. [Preliminary Efficacy Evaluation of Neoadjuvant Immunotherapy Combined with
Chemotherapy in Resectable Non-small Cell Lung Cancer].
Zhou S; Hao X; Yu D; Liu S; Cao X; Su C; Song X; Xiao N; Li Y; Yang W; Zhao D; Wang J; Liu Z; Xu S
Zhongguo Fei Ai Za Zhi; 2021 Jun; 24(6):420-425. PubMed ID: 34024062
[TBL] [Abstract][Full Text] [Related]
16. Is major pathologic response sufficient to predict survival in resectable nonsmall-cell lung cancer patients receiving neoadjuvant chemotherapy?
Cai JS; Li S; Yan SM; Yang J; Yang MZ; Xie CL; Li JB; Feng YF; Yang HX; Hou X
Thorac Cancer; 2021 May; 12(9):1336-1346. PubMed ID: 33751832
[TBL] [Abstract][Full Text] [Related]
17. Major Pathologic Response and Prognostic Score Predict Survival in Patients With Lung Cancer Receiving Neoadjuvant Chemotherapy.
Pataer A; Weissferdt A; Correa AM; Vaporciyan AA; Sepesi B; Heymach JV; Berezowska S; Cascone T; Swisher SG
JTO Clin Res Rep; 2022 Nov; 3(11):100420. PubMed ID: 36389133
[TBL] [Abstract][Full Text] [Related]
18. Artificial Intelligence-Powered Assessment of Pathologic Response to Neoadjuvant Atezolizumab in Patients With NSCLC: Results From the LCMC3 Study.
Dacic S; Travis WD; Giltnane JM; Kos F; Abel J; Hilz S; Fujimoto J; Sholl L; Ritter J; Khalil F; Liu Y; Taylor-Weiner A; Resnick M; Yu H; Hirsch FR; Bunn PA; Carbone DP; Rusch V; Kwiatkowski DJ; Johnson BE; Lee JM; Hennek SR; Wapinski I; Nicholas A; Johnson A; Schulze K; Kris MG; Wistuba II
J Thorac Oncol; 2024 May; 19(5):719-731. PubMed ID: 38070597
[TBL] [Abstract][Full Text] [Related]
19. Major pathologic response and RAD51 predict survival in lung cancer patients receiving neoadjuvant chemotherapy.
Pataer A; Shao R; Correa AM; Behrens C; Roth JA; Vaporciyan AA; Wistuba II; Swisher SG
Cancer Med; 2018 Jun; 7(6):2405-2414. PubMed ID: 29673125
[TBL] [Abstract][Full Text] [Related]
20. [The outcome and safety of neoadjuvant PD-1 blockade plus chemotherapy in stage Ⅱ~Ⅲ non-small cell lung cancer].
Liu YT; Gao YS; Mao YS; Jiang J; Yang L; Yang JL; Hu XS; Zhou SY; Qin Y; Shi YK
Zhonghua Zhong Liu Za Zhi; 2020 Jun; 42(6):480-485. PubMed ID: 32575944
[No Abstract] [Full Text] [Related]
[Next] [New Search]
